

To whom it may concern

April 18, 2018

Notification for the determination of investment in share of PeptiStar Inc.

Nissan Chemical Industries, Ltd. (Head Office: Chiyoda-ku, Tokyo; President: Kojiro Kinoshita) announces the investment of 900 million yen for the third-party allotment of shares in PeptiStar Inc. (Head Office: Settsu city, Osaka; President: Kiichi Kubota), which is a Contract Manufacturing Organization (CMO) for the research and commercial manufacture of constrained peptide therapeutics.

PeptiStar Inc. made approximately 11 billion yen in additional funding raised through the allocation of third-party shares on March 30, 2018. Besides, PeptiStar Inc. announced that this CMO project had been selected as one of the grant program of Cyclic Innovation for Clinical Empowerment (CiCLE) by the Japan Agency for Medical Research and Development's (AMED) and would receive a budget of 9 billion yen. Based on these funds, PeptiStar Inc. promotes establishment of CMO business for the constrained peptide drug.

Nissan Chemical Industries, Ltd. has been developing a novel synthetic method of constrained peptides to reduce the manufacturing cost of goods dramatically. We believe that our research activities will strengthen PeptiStar's and our international competitiveness further in the field.

Contact information for inquiries on the above
Nissan Chemical Industries, Ltd. Corporate Planning Department CSR & Public Relations Office TEL: +81-3-3296-8320 E-mail: csr_pr@nissanchem.co.jp